Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a clinical-stage biopharmaceutical company with a strong focus on developing treatments for central nervous system disorders. Its innovative drug candidate, ML-007C-MA, has shown promising results in early studies and has the potential to generate significant revenue by 2035. Additionally, the company's experienced management team and unique drug discovery platform make it a promising investment opportunity for future success in the field of neuroscience.

Bears say

MapLight Therapeutics is poised for potential success in the biopharmaceutical industry with their development of novel drugs targeting muscarinic receptors in central nervous system disorders. Despite being a clinical-stage company, their drug candidate ML-007C-MA is showing positive results in Phase 2 trials for Alzheimer's disease and schizophrenia. Additionally, their focus on developing drugs for underserved disorders such as autism spectrum disorder sets them apart from other companies in the space.

MPLT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 7 analysts, MPLT has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.